Payment overview · 2025
General Payments
$458.82
23 reported records · 13 companies
Healthcare provider profile · identity verified
Jonathan T Feist, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BATESVILLE, IN · NPI 1427462969
Verified facts
What the public records show
CMS Open Payments records show Jonathan T Feist, M.D. received $458.82 in general payments during 2025 across 23 reported records.
Vanda Pharmaceuticals Inc. accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $82.14 | 17.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.23 | 13.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.50 | 11.4% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $46.31 | 10.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.60 | 8.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.74 | 7.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $32.50 | 7.1% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $24.64 | 5.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.45 | 4.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.26 | 3.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.35 | 3.6% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $15.73 | 3.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.37 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $458.82 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $82.14 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $61.23 | 3 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $46.31 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $40.60 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.74 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $32.50 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.83 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 141 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
141 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 560 | 144 |
| Lisinopril | Lisinopril | 366 | 95 |
| Omeprazole | Omeprazole | 317 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 306 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 295 | 54 |
| Metformin Hcl | Metformin Hcl | 253 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 194 | 53 |
| Losartan Potassium | Losartan Potassium | 168 | 45 |
| Gabapentin | Gabapentin | 163 | 36 |
| Sertraline Hcl | Sertraline Hcl | 158 | 30 |
| Ozempic | Semaglutide | 141 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 41 |
| Eliquis | Apixaban | 129 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 32 |
| Furosemide | Furosemide | 124 | 32 |
| Prednisone | Prednisone | 119 | 75 |
| Simvastatin | Simvastatin | 118 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 114 | 35 |
| Glimepiride | Glimepiride | 113 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 23 |
| Famotidine | Famotidine | 107 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 100 | 29 |
| Montelukast Sodium | Montelukast Sodium | 99 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 22 |
| Alprazolam | Alprazolam | 78 | 18 |
| Allopurinol | Allopurinol | 76 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 15 |
| Spironolactone | Spironolactone | 75 | 16 |
| Xarelto | Rivaroxaban | 73 | 15 |
| Atenolol | Atenolol | 71 | 20 |
| Carvedilol | Carvedilol | 70 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 16 |
| Celecoxib | Celecoxib | 68 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 16 |
| Meloxicam | Meloxicam | 63 | 21 |
| Mirtazapine | Mirtazapine | 62 | 14 |
| Buspirone Hcl | Buspirone Hcl | 60 | 14 |
| Farxiga | Dapagliflozin Propanediol | 60 | 14 |
| Potassium Chloride | Potassium Chloride | 58 | 14 |
| Trazodone Hcl | Trazodone Hcl | 58 | 15 |
| Bupropion Xl | Bupropion Hcl | 57 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 43 |
| Tramadol Hcl | Tramadol Hcl | 56 | 17 |
| Alendronate Sodium | Alendronate Sodium | 53 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 15 |
| Azithromycin | Azithromycin | 49 | 41 |
| Ezetimibe | Ezetimibe | 49 | suppressed |
| Clonazepam | Clonazepam | 47 | suppressed |
| Ondansetron Odt | Ondansetron | 44 | 12 |
| Cephalexin | Cephalexin | 42 | 35 |
| Donepezil Hcl | Donepezil Hcl | 41 | 11 |
| Chlorthalidone | Chlorthalidone | 40 | 12 |
| Cefdinir | Cefdinir | 39 | 34 |
| Methocarbamol | Methocarbamol | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Ramipril | Ramipril | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Mupirocin | Mupirocin | 25 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 16 |
| Pregabalin | Pregabalin | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 16 |
| Lorazepam | Lorazepam | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Nabumetone | Nabumetone | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Alprazolam Er | Alprazolam | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nystatin | Nystatin | 12 | 11 |
| Risperidone | Risperidone | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $458.82 · 23 records | Vanda Pharmaceuticals Inc. | Cologuard Collection Kit, FANAPT, FREESTYLE LIBRE 3, INJECTAFER, INSPIRE, Kerendia, MOUNJARO, Ohtuvayre, Ozempic, Rybelsus, TRELEGY ELLIPTA, Veozah, Wegovy, ZEPBOUND, ZURZUVAE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error